Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05405075 · ClinicalTrials.gov registry record
Arizona Alzheimer's Disease Research Center (ADRC)
A clinical trial of Alzheimer Disease, sponsored by Banner Health.
- Recruiting
- Registry status
- 550
- Enrollment target
- 5
- Study locations
NCT05405075 is a study of Alzheimer Disease that is actively recruiting participants, run by Banner Health. The registered enrollment target is 550 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (80% lower). The trial reports 5 study locations across 1 state.
The verdict
NCT05405075, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Banner Health.
- RECRUITING
- Registry status
- 550 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Arizona Alzheimer's Disease Research Center (ADRC) is the National Institute on Aging's (NIA's) first statewide AD Center (ADC), the only ADC in the Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on Arizona's strengths in brain imaging, genomics, computer science and biomathematics, the basic, cognitive and behavioral neurosciences, clinical, and neuropathological studies of AD, the discovery and evaluation of investigational treatments, and the study of normal cognitive aging.
Conditions Studied
Study Locations (5)
Arizona
- Banner Alzheimer's Institute - Phoenix
- Barrow Neurological Institute - Phoenix
- Mayo Clinic - Scottsdale
- Banner Sun Health Research Institute - Sun City
- Banner Alzheimer's Institute - Tucson - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2026-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05405075
The ClinicalTrials.gov registry entry for NCT05405075 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (80% lower). The listed sponsor is Banner Health, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 0 interventions.
NCT05405075 reports 5 study locations spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT05405075 about?
NCT05405075 is a clinical study titled "Arizona Alzheimer's Disease Research Center (ADRC)". The Arizona Alzheimer's Disease Research Center (ADRC) is the National Institute on Aging's (NIA's) first statewide AD Center (ADC), the only ADC in the Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on Arizona's strengths in brain...
What is the current status of trial NCT05405075?
This trial is currently recruiting. The enrollment target is 550 participants. The study started on 2021-10-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05405075 study?
This clinical trial studies the following conditions: Alzheimer Disease.
Who is sponsoring clinical trial NCT05405075?
This trial is sponsored by Banner Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05405075 being conducted?
This trial has 5 study locations across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.